(NASDAQ: VIGL) Vigil Neuroscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Vigil Neuroscience's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VIGL's revenue for 2026 to be $2,774,155,981, with the lowest VIGL revenue forecast at $2,774,155,981, and the highest VIGL revenue forecast at $2,774,155,981. On average, 2 Wall Street analysts forecast VIGL's revenue for 2027 to be $3,341,215,119, with the lowest VIGL revenue forecast at $2,025,077,860, and the highest VIGL revenue forecast at $4,657,352,378.
In 2028, VIGL is forecast to generate $5,948,287,008 in revenue, with the lowest revenue forecast at $5,948,287,008 and the highest revenue forecast at $5,948,287,008.